EpiVax Announces Licensing of COVID-19 Vaccine Candidate to EpiVax Therapeutics

PROVIDENCE, R.I., Aug. 25, 2020 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), a Rhode Island-based company and recognized leader in the field of computational vaccinology, today announced it has out-licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics ("EVT"), a New York-based company previously named EpiVax Oncology.

https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg [https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg]

Scientists at EpiVax designed EPV-CoV-19 - a peptide-based, epitope-driven vaccine - utilizing their validated computational toolkit (iVAX), which enabled the selection of sequences representing all circulating SARS-CoV-2 genomes that will drive a T cell-mediated immune response, with the goal of providing recipients with immune system "body armor", reducing their risk of severe COVID-19 disease.

With in-licensing the COVID-19 vaccine program, EVT is broadening its pipeline and application of its platform beyond its clinical-stage personalized cancer vaccine program. The venture-backed company will provide an ideal environment for funding and development of EPV-CoV-19. The company recently re-organized its executive team in preparation for the pipeline expansion and is raising $3M to support the new program.

Having received a positive pre-IND response from the FDA, EVT is progressing to a clinical trial. It has begun GMP peptide production and is preparing the IND submission in parallel.

Michael Princiotta, CSO at EVT, said, "EVT is pleased to welcome the COVID-19 vaccine program into our pipeline. We are eager to apply our vaccine platform and fundraising experience to advance EPV-CoV-19 into clinical trials."

Annie De Groot, CEO/CSO and cofounder of EpiVax, said, "The EpiVax team has done a fantastic job in the preclinical research phase. We are confident that EPV-CoV-19 will be safe and effective for frontline healthcare workers. We look forward to working with EVT to accelerate its progress to Phase I and beyond."

About EpiVax: EpiVax has pioneered the use of in silico immunogenicity screening toolkits for therapeutics and vaccines. These toolkits, ISPRI and iVAX, are used for advancing product development at a global roster of companies. See the latest peer-reviewed publications at https://www.frontiersin.org/articles/10.3389/fimmu.2020.00442/full [https://c212.net/c/link/?t=0&l=en&o=2898784-1&h=12027929&u=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2020.00442%2Ffull&a=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2020.00442%2Ffull] and https://www.frontiersin.org/articles/10.3389/fimmu.2020.01301/full [https://c212.net/c/link/?t=0&l=en&o=2898784-1&h=2731707875&u=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2020.01301%2Ffull&a=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2020.01301%2Ffull] for more information about recent applications of EpiVax's in silico vaccine design and protein therapeutic immunogenicity assessment tools.

About EVT: EVT, founded in 2017, employs a world-leading technology, developed over 22 years by EpiVax, to design vaccines that aim to activate the body's T cells to cure or prevent disease in the host. EVT's pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.

Press Contact: Annie De Groot, MD CEO/CSO, EpiVax T : 401-272-2123 E: AnnieD@epivax.com

Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg [https://c212.net/c/link/?t=0&l=en&o=2898784-1&h=775455576&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F542055%2FEpiVax_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F542055%2FEpiVax_Logo.jpg]

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234